(1) Company Name: FerroptoCure Inc.
(2) CEO: Yuji Otsuki
(3) Location:
Head Office:Fujimi Duplex B's 4F, 1-3-11 Fujimi, Chiyoda-ku, Tokyo
Research Laboratory:Nano Medical Innovation Center (iCONM),
3-25-14 Tonomachi, Kawasaki-ku, Kawasaki city, Kanagawa
FerroptoCure Australia Pty Ltd:Level 23, 68 Pitt Street, Sydney NSW 2000,
AustraliaModoras Accounting (SYD) Pty Ltd内）
(4) Established: May 2022
(5) Business Description: Drug discovery targeting ferroptosis
(6) Capital: JPY 10,000,000
(7)Company History
Keio University Gene Regulation Research Division (Saya Lab)
(R&D) Stabilization of xCT by CD44v on cancer cell membranes
(R&D) Antioxidant accumulation in CD44v-positive cells
(Clinical) Human POC with chemo + sulfasalazine (PR patients & PFS prolongation)
(R&D) Contribution of ALDH for xCT inhibitor resistant cancers
(IPs) Synthetic lethality by sulfasalazine and oxyfedrine
Foundation of FerroptoCure
Seed round $3.8M
(Clinical)Initiation of the Ph1 clinical trial for FC001
Initiation of developing FC004
Series A+Strengthening Program for Pharmaceutical Startup Ecosystem: $6.4M
Foundation of Australian subsidiary